Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case report.
177Lu-PSMA
TKTL1
benfo-oxythiamine
case report
metastatic castration-resistant prostate cancer
radiosensitizer
thiamine antagonist
transketolase
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2024
2024
Historique:
received:
09
07
2024
accepted:
28
08
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Herein we report, for the first time, the therapeutic response of a prostate cancer patient with the thiamine antagonist benfo-oxythiamine (B-OT) added to prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT). The patient was initially diagnosed as pT3b pN0 (0/7) M0 L0 V0 R0 G3, Gleason score 5 + 5 = 10, with an initial prostate-specific antigen (PSA) level of 4.05 ng/ml. Shortly after radical prostatectomy,
Identifiants
pubmed: 39444815
doi: 10.3389/fmed.2024.1462234
pmc: PMC11496175
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
1462234Informations de copyright
Copyright © 2024 Kramer, Zhang and Baum.
Déclaration de conflit d'intérêts
RB is a shareholder of Benfovir AG and Oxy5 OncoMedical AG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.